As per the research reports, the size of the Europe Competent Cells Market is valued at USD 0.26 billion in 2021 and estimated to grow at a CAGR of 9.5%, to reach USD 0.41 billion by 2026 during the forecast period 2021 to 2026.
The Europe Competent Cells market is developing at an exceptionally quick pace. Cells are made competent by a technique that uses calcium chloride and high-temperature shock. In genetics and molecular biology, competence is the ability of a cell to take up extracellular (isolated) DNA from its atmosphere in the procedure called transformation. E. coli cells are more likely to incorporate external DNA if their cell walls are transformed so that DNA can pass through more easily.
Expansions in biomolecular cloning study due to the arrival of new technologies and the growing commercial demand for molecular cloned products and recombinant proteins are some of the key factors driving the development of this market. However, rising market consolidation creating strong entry barriers, and the huge cost of competent cell setup is limiting the growth of this market.
This research report segmented and sub-segmented into the following categories:
Cloning is estimated to command the major share of this market in 2017. Increasing study on cloning, driven by government funding is among the major reasons driving market growth in this segment. In 2016, the academic research institutes segment is likely to have the largest share of the market.
Europe had a low CAGR as compared to other regions except for MEA during the forecast period. The reasons for the same might be government policies.
Key players operating in the Europe Competent Cells Market profiled in this report are BioDynamics Laboratory, Inc. (Japan), GCC Biotech (India), SMOBIO Technology (Taiwan), Thermo Fisher Scientific, Inc. (the U.S), QIAGEN N.V. (Germany), OriGene Technologies (U.S.), Merck KGaA (Germany), Promega Corporation (U.S.), Bioline (U.K.), Zymo Research (U.S.), are the leaders in the Europe Competent Cells market.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type
5.1.1 Chemically
5.1.2 Electrocompetent
5.1.3 Y-o-Y Growth Analysis, By Type
5.1.4 Market Attractiveness Analysis, By Type
5.1.5 Market Share Analysis, ByType
5.2 Application
5.2.1 Cloning
5.2.1.1 Subcloning & Routine Cloning
5.2.1.2 Phage Display Library Construction
5.2.1.3 Toxic/Unstable Dna Cloning
5.2.1.4 High-Throughput Cloning
5.2.2 Protein Expression
5.2.3 Other Applications
5.2.3.1 Mutagenesis
5.2.3.2 Large Plasmid Transformation
5.2.3.4 Single-Stranded Dna Production
5.2.3.5 Lentiviral Vector Production
5.2.7 Y-o-Y Growth Analysis, By Application
5.2.8 Market Attractiveness Analysis, By Application
5.2.9 Market Share Analysis, By Application
5.3 End User
5.3.1 Pharmaceutical Companies
5.3.2 Academia
5.3.3 Y-o-Y Growth Analysis, By EndUser
5.3.4 Market Attractiveness Analysis, By EndUser
5.3.5 Market Share Analysis, By EndUser
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Type
6.1.3.3 By Application
6.1.3.4 By EndUser
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Type
6.1.4.3 By Application
6.1.4.4 By EndUser
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Type
6.1.5.3 By Application
6.1.5.4 By EndUser
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 BioDynamics Laboratory, Inc. (Japan)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 GCC Biotech (India)
8.3 SMOBIO Technology (Taiwan)
8.4 Thermo Fisher Scientific, Inc. (U.S)
8.5 QIAGEN N.V. (Germany)
8.6 OriGene Technologies (U.S.)
8.7 Merck KGaA (Germany)
8.8 Promega Corporation (U.S.)
8.9 Bioline (U.K.)
8.10 Zymo Research (U.S.)
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
